StreetAlpha.app
Home › Stocks › ELTX

Elicio Therapeutics, Inc. (ELTX)

Healthcare
$1.45
▼ −3.33%
LAST CLOSE · NOV 20

Elicio Therapeutics is a Boston biotech developing lymph node targeted cancer immunotherapies, mainly for cancers with mutant KRAS. It last closed at $1.45 on Nov 20, down 3.33% on the day. The next earnings report for ELTX is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, ELTX reported EPS of -$0.30. Over its last 8 reports the stock moved an average of 7.6% the session after earnings.

AI Auto Pilots
Is ELTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ELTX.

Key Stats

Last 12 months
Results
Net income
−$35.7M
EPS (diluted)
−$1.81
Valuation
Market cap
$41.0M
28.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$30.9M
At Sep 30
Debt
$9.6M
At Sep 30
Shareholder equity
$18.9M
Shares outstanding
28.3M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$54.6M−$54.6MFY2021FY2022: −$28.2M−$28.2MFY2022FY2023: −$35.2M−$35.2MFY2023FY2024: −$51.9M−$51.9MFY2024FY2025: −$39.6M−$39.6MFY2025

From ELTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$0.30
Quarter ended Sep 2026
Year ago EPS
-$0.60
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.02Dec '24Mar 2025: -$0.87Mar '25Jun 2025: -$0.66Jun '25Sep 2025: -$0.60Sep '25Dec 2025: -$0.49Dec '25Mar 2026: -$0.65Mar '26Jun 2026: -$0.43Jun '26Sep 2026: -$0.30Sep '26Latest -$0.30
Revenue by quarter
Not enough quarters on file yet.
How ELTX moved after its last 8 reports
Average move the session after a report ±7.6%
Nov 5, 2026After the close+7.9%
Aug 13, 2026After the close−1.9%
May 11, 2026After the close−9.1%
Mar 12, 2026After the close+11.9%
Nov 13, 2025After the close−2.2%
Aug 7, 2025After the close+1.4%
May 13, 2025After the close−5.3%
Mar 31, 2025Time not announced−20.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ELTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ELTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ELTX

Technical Analysis

ELTX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 10% below its 20 day and 20% below its 50 day average. It is 334% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 41). The nearest support is the swing low (Oct 19) at $1.44, and the nearest resistance the Pivot at $1.49.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 12.2%/day
Key levels
$16.0052 week high+1003.4%
$6.30200 day average+334.5%
$2.35100 day average+62.1%
$1.77Swing high (Nov 10)+22.1%
$1.7450 day average+20.0%
$1.5920 day average+9.7%
$1.55Pivot R1+6.9%
$1.49Pivot+2.8%
$1.45Last close
$1.44Swing low (Oct 19)−0.7%
$1.40Pivot S1−3.4%
$1.2552 week low−13.8%
Indicators
RSI (14)40.74Middle of its rangeNeutral
MACD-0.09Above its signal lineBullish
Stochastic48.6Middle of its rangeNeutral
ADX (14)27.2Trending down
Williams %R-61.5Oversold below −80, overbought above −20Neutral
CCI (20)-71.8Oversold below −100, overbought above 100Neutral
Rate of change−4.0%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ELTX

What happened before

See how ELTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ELTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ELTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ELTXHow many large options trades hit ELTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ELTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲59 buying vs 12 selling
  • ▲Held by funds +12.0 pts
  • ▲Funds holding +32
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8149+65.3%
In funds' top 1010–
Held by funds25.9%13.9%+12.0 pts
New / increased37 / 2224 / 14+55.3%
Reduced / sold out7 / 52 / 23−52.0%
Put/call ratio17.770.61+2804.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ELTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELTX is in one of them and how their past ELTX trades turned out.

ELTX in the AI portfolios
Loading…

ELTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ELTX in an article yet. Here's the latest on the wider market.

ELTX in the news

About Elicio Therapeutics

Elicio Therapeutics is a biotechnology company based in Boston, Massachusetts, that is developing cancer immunotherapies. Its lead candidate, ELI-002 7P, is in clinical trials for pancreatic cancer and is also being studied in colorectal cancer. The company's treatments are designed to deliver immune signals to lymph nodes to generate T cell responses against tumors. Its target patients are those with cancers driven by mutant KRAS, a gene mutation found in many solid tumors.

Headquarters
Boston, MA